Saturday, July 11, 2026

Drug profile · INN

dexrazoxane

dexrazoxane (SAVENE) is a dna topoisomerase ii inhibitor.

EMA: approved Various (V03) V03AF02
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — dexrazoxane
Class
Various (V03)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

dexrazoxane (SAVENE) is a dna topoisomerase ii inhibitor.

Key facts

INN dexrazoxane
Brand SAVENE
Mechanism DNA topoisomerase II inhibitor
Target DNA topoisomerase II
Therapeutic class Various (V03)
ATC code V03AF02

Mechanism of action

DNA topoisomerase II inhibitor

Primary target: DNA topoisomerase II

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. UC-0103/1802 Phase 3 · Ningbo Cancer Hospital · Advanced or metastatic soft tissue sarcoma (STS) in patients

Related & competitor drugs

  1. besilesomab Various (V09)
  2. deferasirox Various (V03)
  3. etoposide DNA topoisomerase II inhibitor
  4. ferric citrate coordination complex Various (V03)
  5. folic acid Various (V04)
  6. sevelamer carbonate Various (V03)

Frequently asked questions

What is dexrazoxane?

dexrazoxane (SAVENE) is a dna topoisomerase ii inhibitor.

What is the brand name for dexrazoxane?

SAVENE is a marketed brand name for dexrazoxane. Check FDA Drugs@FDA for the current US label holder and prescribing information.